Skip to main content
Premium Trial:

Request an Annual Quote

Zephyr AI Raises $111M in Series A Financing Round

NEW YORK – Zephyr AI on Wednesday said it has raised $111 million in a Series A financing round to support its efforts to develop artificial intelligence algorithms for precision medicine.

Eli Lilly, Revolution Growth, Jeff Skoll, and EPIQ Capital Group participated in the funding round. In 2022, the company closed a $18.5 million seed financing round.

The McLean, Virginia-based bioinformatics startup said the financing will allow it to create algorithms and strengthen datasets for training and validating its tools, as well as hire experts within its scientific and commercial teams. Specifically, the company is developing a technology platform that uses AI to aggregate and analyze datasets that can inform drug discovery and improve care for patients with cancer and cardiometabolic diseases. Zephyr AI is using this platform to glean insights that can help stratify patients and predict their responses to treatments.

"The expansion of our diverse multimodal data resources will accelerate the advancement of Zephyr AI's algorithms, paving the way for us to transform the landscape of precision medicine and improve outcomes for our partners and patients," Jeff Sherman, Zephyr AI's cofounder, interim CEO, and chief technology officer, said in a statement.

Zephyr AI said it has two abstracts accepted for publication at the American Association for Cancer Research's annual meeting in April, in which researchers describe the utility of real-world clinicogenomics data and augmentation of molecular data from commercial genetic panels.